Skip to content
10-Q

Quarterly Report

KalVista Pharmaceuticals, Inc. KALV

0001193125-25-200757

← back to feed
Filed
Sep 11, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Aug 29, 2025 50.52M sh
Shares Diluted Q1 2026 · Jul 31, 2025 53.5M sh
Shares Diluted Q1 2026 · Jul 31, 2024 46.23M sh
Capex Q1 2026 · Jul 31, 2025 $290K
Capex Q1 2026 · Jul 31, 2024 $21K
Operating Cash Flow Q1 2026 · Jul 31, 2025 −$54.5M
Operating Cash Flow Q1 2026 · Jul 31, 2024 −$40.22M
Cash And Equivalents Q1 2026 · Jul 31, 2025 $124.3M
Cash And Equivalents Q1 2026 · Apr 30, 2025 $131.62M
Cash And Equivalents Q1 2026 · Jul 31, 2024 $31.85M
Stockholders Equity Q1 2026 · Jul 31, 2025 $40.79M
Stockholders Equity Q1 2026 · Apr 30, 2025 $95.39M
Stockholders Equity Q1 2026 · Jul 31, 2024 $172.8M
Stockholders Equity Q1 2026 · Apr 30, 2024 $206.58M
Current Liabilities Q1 2026 · Jul 31, 2025 $38.38M
Current Liabilities Q1 2026 · Apr 30, 2025 $45.17M
Current Assets Q1 2026 · Jul 31, 2025 $205.9M
Current Assets Q1 2026 · Apr 30, 2025 $241.69M
Total Assets Q1 2026 · Jul 31, 2025 $215.51M
Total Assets Q1 2026 · Apr 30, 2025 $250.77M
Eps Diluted Q1 2026 · Jul 31, 2025 −$1.12
Eps Diluted Q1 2026 · Jul 31, 2024 −$0.87
Eps Basic Q1 2026 · Jul 31, 2025 −$1.12
Eps Basic Q1 2026 · Jul 31, 2024 −$0.87
Sga Expense Q1 2026 · Jul 31, 2025 $44.68M
Sga Expense Q1 2026 · Jul 31, 2024 $17.6M
Rd Expense Q1 2026 · Jul 31, 2025 $15.16M
Rd Expense Q1 2026 · Jul 31, 2024 $26.61M
Net Income Q1 2026 · Jul 31, 2025 −$60.1M
Net Income Q1 2026 · Jul 31, 2024 −$40.44M
Operating Income Q1 2026 · Jul 31, 2025 −$59.01M
Operating Income Q1 2026 · Jul 31, 2024 −$44.22M
Revenue Q1 2026 · Jul 31, 2025 $1.43M